Medicine and Health Sciences Commons^™

Bayer Ag V. Housey Pharmaceuticals: Protection For Biotechnological Research Tools Under Section 271(G) Found Wanting, Matthew Barthalow

The University of New Hampshire Law Review

[Excerpt] "Research tools, a subset of biotechnological inventions protected by process patents, are “tools that scientists use in the laboratory, including cell lines, monoclonal antibodies, reagents, animal models, growth factors, combinatorial chemistry and DNA libraries, clones and cloning tools (such as PCR), methods, laboratory equipment and machines.” Many companies base their business models on the ability to find pharmaceutical products using their proprietary drug discovery research tools. Research tools used for drug discovery ‘include bioinformatic methods for identifying the interaction of certain proteins and their association with disease, methods for confirming protein targets, screening assays to identify molecules active against …

Editor's Note, Padraig O'Malley

New England Journal of Public Policy

This issue of the journal can be summed up in one word: provocative. At least two articles break new ground. Anthony Robbins and Phyllis Freeman explore the ways in which environmentally oriented public health is uniquely suited to help organized medical care in providing health and in restraining expenditures. Janet Farrell Smith challenges policymakers to look at what will soon become a hot issue — the medical use of genetic information. The genetic testing of children, now becoming prevalent in the foster care and pre-adoptive stage in order to facilitate placement and satisfy prospective parents’ “need to know,” is already …

Genetic Testing: A Cautionary Tale Of Foster And Pre-Adoptive Children, Janet Farrell Smith

New England Journal of Public Policy

Genetic testing of children in the foster care and pre-adoptive stage may be thought to facilitate child placement and satisfy prospective parents’ need to know. But, the policy analysis in this paper recommends great caution, especially given eugenic attitudes in the history of adoption and the risk of creating a second tier of un-adoptable children. Testing should be done only when two conditions are satisfied: test information is medically useful for childhood onset diseases; test information supports and does not diminish the child’s access to present and future healthcare (or the child’s future insurability). Public policy needs to make a …

Review Of: The Human Genome Project And Minority Communities - Ethical, Social, And Political Dilemmas (Raymond A. Zilinskas & Peter J. Balint Eds.), Craig Steven Jepson

RISK: Health, Safety & Environment (1990-2002)

Review of the book: The Human Genome Project and Minority Communities -Ethical, Social, and Political Dilemmas (Raymond A. Zilinskas & Peter J. Balint eds., Praeger Publishers 2001). Preface, index, about the contributors. LC 00-032390; ISBN 0-275-96961-4 [160 pp. $54.50.Cloth, 88 Post Road West, Westport, CT 06881].

Genetic Monitoring In The Workplace: A Tool Not A Solution, Lillian Trettin, Catherine Musham, Richard Jablonski

RISK: Health, Safety & Environment (1990-2002)

The authors differentiate between genetic monitoring and screening, and discuss the potential risks and benefits of predictive testing technologies.

Genome Research And Traditional Intellectual Property Protection -- A Bad Fit?, Kate H. Murashige

RISK: Health, Safety & Environment (1990-2002)

Dr. Murashige addresses the need for a patent system more closely tailored to the needs of biotechnology. For example, the obviousness requirement may interfere with using patents to recoup high costs of work when it could arguably be done by researchers of ordinary skill.

Social Issues Of Genome Innovation And Intellectual Property, Elaine Alma Draper

RISK: Health, Safety & Environment (1990-2002)

Dr. Draper's focus is the use of personal information derived from genome research. She identifies several potential problems, including access to and control of genetic information, employment discrimination and social stratification. She also recommends possible solutions.

Review Of: The Genetic Frontier: Ethics, Law, And Policy (Mark S. Frankel & Albert Teich Eds., American Association For The Advancement Of Science 1994), Suzanne A. Sprunger

RISK: Health, Safety & Environment (1990-2002)

Review of: The Genetic Frontier: Ethics, Law, and Policy (Mark S. Frankel & Albert Teich eds., American Association for the Advancement of Science 1994). Acknowledgments, appendix, contributors, figures, index, introduction, notes, references, tables. LC 93-37230, ISBN 0-87168-526-4. [260 pp. Paper $22.95. 1333 H St., NW, Washington DC 20005.]

Maximizing The Return From Genome Research: Introduction, Thomas G. Field Jr.

RISK: Health, Safety & Environment (1990-2002)

Professor Field introduces and explains the origins of the symposium.

Overview Of Federal Technology Transfer, Lawrence Rudolph

RISK: Health, Safety & Environment (1990-2002)

Mr. Rudolph reviews approximately thirteen years of legal and political developments that have contributed to laws governing the extent to which private firms may secure rights in technology at least partly developed with federal funds.

Technology Transfer: A View From The Trenches, Harvey Drucker

RISK: Health, Safety & Environment (1990-2002)

Dr. Drucker, who has lab-wide responsibility for technology transfer at Argonne National Laboratory, argues that transferring rights in discoveries made through tax supported research to private entities can contribute to public welfare in many ways.

Origins Of The Human Genome Project, Robert Mullan Cook-Deegan

RISK: Health, Safety & Environment (1990-2002)

Dr. Cook-Deegan recounts some of the scientific and political history leading to controversy about the proper mix of private and public roles in pursuing genome research and bringing its fruits to bear, e.g., in preventing and curing disease.

Overview Of Potential Intellectual Property Protection For Biotechnology, Kate H. Murashige

RISK: Health, Safety & Environment (1990-2002)

Dr. Murashige compares the function and value of copyright, patent and trade secret laws in recovering investments in developing genome-related biotechnology.

Book Review, Bradley J. Olson

RISK: Health, Safety & Environment (1990-2002)

Review of: JOHN HARRIS, WONDERWOMAN AND SUPERMAN: THE ETHICS OF HUMAN BIOTECHNOLOGY. (Oxford University Press 1992) [271 pp.] Acknowledgements, further reading, index, introduction, notes. LC 91-23939; ISBN 0-19-2177540-0. [$22.95 cloth. 200 Madison Avenue; New York NY 10016.]

Book Review, Bradley J. Olson

RISK: Health, Safety & Environment (1990-2002)

Review of the following: THE CODE OF CODES: SCIENTIFIC AND SOCIAL ISSUES IN THE HUMAN GENOME PROJECT. (Daniel J. Kevles & Leroy Hood, eds., Harvard University Press 1992) [397 pp.] Contributors, figures, index, notes, preface, selected bibliography, tables. LC 91-38477, ISBN 0- 674-13645-4. [Cloth $29.95. 79 Garden Street, Cambridge MA 02138.]

Book Review, Kristin S. Shrader-Frechette

RISK: Health, Safety & Environment (1990-2002)

Review of the following: ELAINE DRAPER, Risky BUSINESS: GENETIC TESTING AND EXCLUSIONARY PRACTICES IN THE HAZARDOUS WORKPLACE. (Cambridge University Press 1991) [315 pp.] Index of names and subjects, glossary, notes, references. LC 90-28112; ISBN 0-521-37027-2 (cloth $49.50); ISBN 0-42248-5 (paper $15.95). [40 W. 20th St., New York NY 10011.]

Herd Improvement Service Forges Ahead, M P. Bond

Journal of the Department of Agriculture, Western Australia, Series 4

Since its establishment three years ago, the Herd Improvement Service has steadily expanded the range of services provided to Western Australian livestock producers. The genetic advancement and improved hers management offered by the service give farmers the ability to use modern technology in the most cost-effective way. There is an increasing realisation amongst farmers that to survive and remain competitive, it is worthwhile to invest in such technology.

The Herd Improvement Service is a statutory corporation which was formed to improve the productivity of the State's livestock enterprises. Most of the organisation's activities have been directed to servicing the dairy …

The Recombinant Dna Controversy: A Contemporary Cautionary Tale, Nina V. Fedoroff

Syracuse Scholar (1979-1991)

A discussion of the scientific and political aspects of recombinant DNA research.

Cancer Eye Of Cattle, M R. Gardiner, J. L. Anderson, D. E. Robertson

Journal of the Department of Agriculture, Western Australia, Series 4

Cancer of the eye and eyelids is mainly a disease of cattle, although it occasionally occurs in most species of animals and in man. It is the most common cancer in cattle, especially in certain breeds.

Later Mating Improves Lambing Results, R J. Suiter

Journal of the Department of Agriculture, Western Australia, Series 4

Ovulation studies in Western Australia have indicated that increased lambing percentages in crossbred and Merino ewes could be expected from mating in February-April rather than December- January.

Such increases have been demonstrated in time of lambing trials with crossbred ewes, but had not been seen in Merino flocks until recently.

This report summarises the results of time of lambing trials with Merinos carried out at the Merredin and Wongan Hills Research Stations between 1963 and 1969.

Causes Of Low Lambing Percentages, Department Of Agriculture, Western Australia

Journal of the Department of Agriculture, Western Australia, Series 4

West Australian Merino flocks average about 70 per cent, lambs marked each year. Reasons for this low percentage are that as many as 30 per cent, of ewes do not lamb, twinning rates are low and from 10 to 25 per cent, of lambs born die.

Among the research projects by the Department of Agriculture's Sheep and Wool Branch have been a number directed at the various stages of reproduction in the ewe. These have given some important leads on the causes of low lambing percentages.

If you have marked less than 60 per cent, lambs in the past several …